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In a multicenter trial, renal transplant recipients were randomized to tacrolimus with ﬁxed-dose sirolimus (Tac/SRL, N = 318)
or tacrolimus with MMF (Tac/MMF, N = 316). Targeted tacrolimus trough levels were lower in the Tac/SRL group after day
14. The primary endpoint was renal function at 6 months using creatinine clearance (Cockcroft-Gault) and was comparable at
66.4mL/min (SE 1.4) with Tac/SRL and at 65.2mL/min (SE 1.3) with Tac/MMF (completers). Biopsy-conﬁrmed acute rejection
was 15.1% (Tac/SRL) and 12.3% (Tac/MMF). In both groups, graft survival was 93% and patient survival was 99.0%. Premature
withdrawal due to an adverse event was twice as high in the Tac/SRL group, 15.1% versus 6.3%. Hypercholesterolemia incidence
was higher with Tac/SRL (P<. 05) while CMV, leukopenia, and diarrhea incidences were higher with Tac/MMF (P<. 05). The
incidence of any antidiabetic treatment for > 30 consecutive days in previously nondiabetic patients was 17.8%, Tac/SRL, and
24.8%, Tac/MMF. Evaluation at 6 months showed comparable renal function using tacrolimus/sirolimus and tacrolimus/MMF
regimens.2 Journal of Transplantation
1.Introduction
Tacrolimus combined with various adjunctive agents has
been evaluated in clinical trials. Studies have shown that
tacrolimus provides good renal allograft function and excel-
lent immunologic protection [1, 2] and combined with
MMF has proved to be a highly eﬃcacious regimen in renal
transplantation [3, 4] which is now the standard regimen in
most transplant centers in Europe and the US.
Clinical comparisons of eﬃcacy outcomes between
tacrolimus with sirolimus and tacrolimus with MMF have
demonstrated similarly low incidences of biopsy-conﬁrmed
acute rejection (BCAR). The results of one large multicenter
European study revealed comparable BCAR rates between
regimens using 0.5mg sirolimus and 1.0gMMF but
signiﬁcantly lower incidences of BCAR when a 2mg dose of
sirolimus was administered [5]. A randomized clinical trial
conducted in the US found low and comparable rates of
BCAR using 2.0mg sirolimus and 2.0g MMF (13.0% and
11.4%, resp.) [6]. Results of safety analyses in both studies,
however, revealed more adverse eﬀects with sirolimus
than with MMF, including higher measurements of some
indicators of cardiovascular risk.
Combining sirolimus with a calcineurin inhibitor (CNI)
may accelerate CNI-induced nephrotoxicity especially in the
presence of delayed graft function (DGF) [7]. The results of
one clinical trial showed signiﬁcantly worse renal function
with a tacrolimus and sirolimus combination compared
with a tacrolimus and MMF combination using sirolimus
2mg daily [6]. In contrast, a phase II study compared
three maintenance doses of sirolimus (0.5mg, 1mg, and
2mg daily) combined with tacrolimus against a standard
tacrolimus and steroid regimen and found no diﬀerence in
serum creatinine [8].
In this multicenter, randomized, clinical trial, we used
renal function, as measured by calculated creatinine clear-
ance at 6 months, to compare tacrolimus combined with
sirolimus against a tacrolimus and MMF control. Our sec-
ondary objective was to compare the eﬃcacy and safety pro-
ﬁles of the two regimens. Unlike other studies, sirolimus was
administered in a ﬁxed dose, as opposed to a concentration-
controlled dosing concept, and a maintenance dose of 1.0mg
sirolimus was initiated after 28 days.
2. Patientsand Methods
This was a 6-month, randomized, phase III clinical trial
conducted in 51 centers in 13 European countries. The study
was performed in accordance with the ethical principles
described in the amended Declaration of Helsinki following
approval from the institutional review committee at each
participatingcenter.Patientsprovidedwritteninformedcon-
sent prior to study randomization. The study was conducted
between October 2004 and July 2006.
Patients aged 18 to 60 undergoing primary renal
transplantation or retransplantation (unless the graft was
lost due to rejection within the previous 12 months)
from a deceased or living donor were eligible for study
enrollment. Excluded from the study were patients with
high immunological risk (deﬁned as having a panel
reactive antibody grade >50% in the previous 6 months
and/or having a previous graft survival <1y e a rd u et o
immunological reasons). Other exclusion criteria included
continuouslyelevatedtestsofliverfunction,patientordonor
was HIV positive, previous recipient of an organ transplant
other than kidney, organ cold ischemia time >30 hours,
intolerance to any of the study drugs or the requirement
of additional immunosuppressive drugs or antibodies,
malignancy, severe hypercholesterolemia (>350mg/dL or
9.1mmol/dL), and uncontrolled infection. Patients provided
written informed consent before study enrollment.
Patient randomization was 1:1, stratiﬁed by center
and occurred before the ﬁrst dose of study medication
was administered. Sealed randomization envelopes were
supplied by the study sponsor. Patients were assigned to
treatment with tacrolimus, sirolimus, and steroids (Tac/
SRL) or tacrolimus, mycophenolate mofetil, and steroids
(Tac/MMF).
Tacrolimus was administered in both treatment groups
at an initial daily dose of 0.2mg/kg administered twice
(one dose preoperatively and one dose postoperatively).
Recommended trough levels for tacrolimus in both groups
on days 0 to 14 were 10–15ng/mL. As the combination of
a CNI and sirolimus has been shown to be potentially more
nephrotoxic than a CNI and MMF [5, 8–10], recommended
tacrolimus trough levels were lower after day 14 in the
Tac/SRL group to minimize toxicity. Trough levels were set
at 4–8ng/mL on days from 15 to 42 and 4–6ng/mL on days
from43to183.RecommendedtroughlevelsintheTac/MMF
group were set higher at 8–12ng/mL on days from 15 to 42
and 5–10ng/mL on days from 43 to 183.
A loading dose of sirolimus 6.0mg was administered
with the postoperative dose of tacrolimus and was followed
by maintenance doses of 2.0mg for 28 days and 1.0mg
thereafter. A loading dose of MMF 1.0g was administered
pretransplant followed by a daily dose of 2.0g for the ﬁrst 14
days and 1.0g daily thereafter. Doses of sirolimus and MMF
couldbereducedorsuspendedduetomedicationsideeﬀects
for no more than 21 days.
Adjuvant treatment with corticosteroids was permitted
in both regimens using a 100–500mg bolus dose given peri-
operatively and a 125mg bolus on day 1. Thereafter, steroids
w e r et ob es t e a d i l yt a p e r e df r o m2 0m go nd a y2t o5m gb y
day 90 and discontinued on day 91.
First line treatment for acute rejection was corticos-
teroids administered according to local practice; antibody
administration was permitted if a biopsy revealed a severe
vascular rejection (Banﬀ IIb or III). If rejection was
refractory to corticosteroids, then treatment with OKT3
or polyclonal antibodies according to local practice was
permitted. Other systemic immunosuppressive medications
were prohibited.
Prophylactic treatment for Pneumocystis carinii pneu-
monia consisting of cotrimoxazole was required throughout
the study. Prophylactic antiviral treatment for CMV in
cases where a CMV-positive donor graft was transplanted
in a CMV-negative recipient consisting of gancyclovir or
equivalent was required.Journal of Transplantation 3
2.1. Outcome Assessments. The primary eﬃcacy endpoint
was renal function as measured by calculated creatinine
clearance at month 6 (Cockcroft-Gault formula [11]). Since
the planning of this study, the Modiﬁcation of Diet in Renal
Disease formula (MDRD) has become increasingly used to
estimate glomerular ﬁltration rate following renal transplan-
tation; hence, a post hoc analysis of the primary endpoint
was run using the MDRD-4 [12]. Secondary endpoints
included the incidence and time to clinical acute rejection
and BCAR, patient and graft survival, incidence of adverse
events, absolute change in serum lipids, renal dysfunction,
and the incidence of diabetes mellitus and hypertension.
The outcomes measured in the study were deﬁned as
follows. Graft loss: retransplantation, nephrectomy, death or
dialysis ongoing at study end or patient withdrawal. DGF:
postoperative dialysis for more than one day during the time
period from day 0 to day 7. Hypertension: systolic blood
pressure >140mmHg or diastolic blood pressure >90mmHg
within one measurement. Diabetes mellitus: antidiabetic
treatment for >30 consecutive days. Safety assessments
included the monitoring of adverse events and vital signs as
well as clinical laboratory evaluations. Adverse events were
coded using MedDRA (version 8.0).
A total of seven scheduled assessment visits took place.
Patients were regularly monitored for adverse events.
2.2. Statistical Analysis. Ad i ﬀerence in the mean creatinine
clearance of 7.5mL/min was considered a clinically mean-
ingful margin of noninferiority. Therefore, it was calculated
that 225 patients would be required per treatment group to
conclude non-inferiority with a power of at least 90%. With
an assumed dropout rate of 25%, 600 patients were to be
randomized, 300 patients per treatment group. A test for
superiority was to be performed without further adjustment
of the level of signiﬁcance if non-inferiority was shown.
The full analysis set (FAS), all patients who were
randomized, transplanted, and received at least one dose of
study medication, was used for analysis. Data from patients
belonging to the FAS who completed the study were used
to analyze the primary endpoint. Because of the potential
bias using observed cases only, a sensitivity analysis of the
primary endpoint was performed on all patients with data
available at 6 months. Missing values of creatinine clearance
were not imputed.
The incidence and time to acute rejection as well as
patient and graft survival were analyzed using Kaplan-Meier
methods. The diﬀerence between treatment groups was ana-
lyzed using the Wilcoxon-Gehan test. Two-sided 95% conﬁ-
dence limits for the diﬀerence in survival at month 6 were
calculated using normal approximation with the variance
calculated according to the Greenwood formula. Secondary
endpoint variables were analyzed using descriptive statistics.
Theincidenceofadverseeventswascomparedbetweentreat-
ment groups using descriptive P-values of Fisher’s exact test.
3. Results
3.1.Patients. Intotal,659patientswereenrolledinthestudy.
Of these, 634 underwent transplantation and received at
least one dose of study medication (tacrolimus, sirolimus,
or MMF), and thus were eligible for the FAS. The treatment
groups were comparable with respect to demographic and
baseline characteristics. The population was European, pre-
dominantly Caucasian with a mean age in the mid-40s, low
immunologic risk, with few comorbidities (Table 1).
Approximately 79% of all randomized patients com-
pleted the study (Figure 1). The most common reason for
s t u d yw i t h d r a w a li nb o t hg r o u p sw a sa na d v e r s ee v e n t .
3.2. Immunosuppression. P r o t o c o l - d e ﬁ n e dt a r g e t e dt a c r o -
l i m u st r o u g hl e v e l sw e r ed i ﬀerent for the two groups after
day 14. Despite lower targeted levels after day 14 in the
Tac/SRL group, mean trough levels remained above the
upper recommended range throughout the study. At month
6,targetedtroughlevelwas4–6ng/mL,whereastheobserved
mean levelwas7.4ng/mL (Figure 2). Inthe Tac/MMFgroup,
mean tacrolimus trough level at month 6 was8.9ng/mL
which was within the targeted range of 5–10ng/mL. Mean
(±SD) daily dose of tacrolimus was similar between the
groups at 6 months: 4.9mg (±3.1) in the Tac/SRL group and
5.2mg (±2.9) in the Tac/MMF group.
The mean (SD) daily administered dose of sirolimus
steadily decreased from 1.7mg (±0.5) at day 28, to 1.0mg
(±0.2) by day 61, and 1.0mg (±0.2) by month 6 (median
dose 1.0; range, 0.3–2.0mg). Similarly, the mean daily dose
of MMF decreased from 1.9g (±0.2) during week 2 to 1.3g
(±0.4) at week 3 and 1.0g (±0.3) at 6 months (median
dose 1.0; range 0.3–2.0g). There were no patients in either
treatment group who violated protocol and discontinued
the adjunct immunosuppressant for >21 days or switched
adjunct immunosuppressant. Four patients in the Tac/MMF
group completely discontinued taking MMF.
Adherencetotheprotocol-deﬁnedwithdrawalofsteroids
at month 3 was low in both groups. At month 4, approx-
imately half of the patients in each group were still taking
steroids. By month 5 the numbers of patients maintained
on steroids dropped dramatically in both groups. This
was 81/318 patients (25.5%) in the TAC/SRL group taking
maintenancesteroidsatamediandailydoseof5.0mg(range,
1.3–82.5) and 99/316 patients (31.3%) in the TAC/MMF
group taking maintenance steroids at a median daily dose of
5.0mg (range, 1.4–36.3). At month 6, maintenance steroids
were being taken by 59/318 patients (18.6%) in the Tac/SRL
group at a median daily maintenance dose of 5.0mg (range,
1.3–25.0) compared with 84/316 patients (26.6%) in the
Tac/MMF group taking a median daily maintenance dose of
5.0mg (range, 0.6–30.0).
3.3. Renal Function. The calculated mean creatinine clear-
ance values at 6 months were similar in the two groups.
In 250/318 patients (completers) in the Tac/SRL group,
the mean creatinine clearance was 66.4mL/min (SE 1.4),
and in 266/316 patients (completers) in the Tac/MMF
group, it was 65.2mL/min (SE 1.3) (Table 2). The lower
boundaryofthetwo-sided95%CIforthediﬀerenceinmean
creatinine clearance was −2.58mL/min which is well within
the predeﬁned margin of −7.5mL/min. Hence, Tac/SRL was4 Journal of Transplantation
Table 1: Patient Demographics and Baseline Characteristics.
Tacrolimus/Sirolimus N = 318 Tacrolimus/MMF N = 316
Recipients
Age, mean (SD), y 44.3 (11.3) 44.9 (11.1)
Range, y 18–66 18–72
Male, Number (%) 204 (64.2) 204 (64.6)
Race, Number (%)
Caucasian 299 (94.0) 303 (95.9)
Black 10 (3.1) 7 (2.2)
Oriental 7 (2.2) 4 (1.3)
Other 2 (0.6) 2 (0.6)
Previous transplants, Number (%)
0 306 (96.2) 301 (95.3)
1 12 (3.8) 14 (4.4)
3 0 (0.0) 1 (0.3)
PRA
a: 0%–50%, Number (%) 316 (99.7) 313 (100.0)
50%–100%, Number (%) 1 (0.3) 0 (0.0)
Donors
Donation type: Number (%)
Living 41 (12.9) 32 (10.1)
Deceased 277 (87.1) 284 (89.9)
Transplant
ABO identical, Number (%) 296 (93.1) 295 (93.4)
Cold ischemia time, mean (SD), h 16.1 (6.1) 16.0 (5.8)
Mean total HLA mismatch 2.9 3.0
CMV status: Donor +/Recipient −, Number (%) 47 (14.8) 57 (18.0)
FAS
aPRA not recorded for all patients.
noninferior to Tac/MMF. The test of superiority of Tac/SRL
over Tac/MMF was not signiﬁcant. Results of the post
hoc analysis using the MDRD-4 formula to estimate renal
function showed no meaningful diﬀerence between the two
treatments although it was notable that mean estimated GFR
as measured by MDRD was lower than calculated creatinine
clearance using the Cockcroft-Gault formula in both groups.
Delayed graft function was reported in 64/318 patients
(20.1%)intheTac/SRLgroupandin52/316patients(16.5%)
in the Tac/MMF group. Of these patients, dialysis was
required by 53 patients (16.7%) in the Tac/SRL group for a
median of 10 days (range: 2–76 days) and by slightly fewer
patients 45 (14.2%) in the Tac/MMF group for a median of
8d a y s( r a n g e2 – 2 6 ) .T h e r ew a sn od i ﬀerence between the
treatment groups in renal function as measured by mean
calculated creatinine clearance in patients with and without
DGF (Table 2). Mean serum creatinine was numerically
better in patients treated with Tac/SRL with notably better
results in the subgroup of patients without DGF.
3.4. Acute Rejection. The overall frequency of acute rejection
diagnosed by either clinical signs, symptoms, or biopsy-
conﬁrmed was similar in the treatment groups (Table 3).
The protocol speciﬁed that biopsies were to be performed
if the patient displayed signs and symptoms of rejection;
however, biopsies were not performed on all suspected
rejections. Incidence of BCAR was 15.1% in the Tac/SRL
group and 12.3% in the Tac/MMF group. There were no
diﬀerences found in either the histological classiﬁcation of
biopsy specimens or in the clinical course of the rejection
episodes.
The overall estimated rate of patients free from BCAR at
6 months (Kaplan-Meier method) was 83.8% in the Tac/SRL
group and 87.1% in the Tac/MMFgroup (diﬀerence between
groups in 6-month survival was −3.0%; 95% conﬁdence
interval: −8.9% to 2.4% [Greenwood formula]). More than
half of the BCARs in each group occurred during the ﬁrst
two weeks after transplant (Figure 3). In the Tac/SRL group
nearly half of BCAR episodes (23/48) occurred during week
one whereas in the Tac/MMF group nearly half of BCAR
episodes (19/39) occurred during week two. During month
3, the number of patients experiencing a BCAR was similar,
(2/48 in the Tac/SRL group and 4/39 in the Tac/MMF group)
whereas acute rejection during month 6 was higher in the
Tac/SRL than in the Tac/MMF group (7/48 versus 2/39
patients, resp.).
3.5. Patient and Graft Survival. Patient and graft survival
wereequivalentbetweentreatmentgroups(Table 3).Kaplan-
Meier estimate for overall patient survival rate was 99.0%
(95% CI: 98.0% to 100%) at month 6 for both treatment
groups. During the study, 4 patients died: 1 patient in theJournal of Transplantation 5
Table 2: Measurements of renal function at month 6.
n Tacrolimus/Sirolimus N = 318 n Tacrolimus/MMF N = 316
Creatinine Clearance (Cockcroft-Gault), mean (SE), mL/min
Patients completing the study 250 66.4 (1.4) 266 65.2 (1.3)
Patients with month 6 data
a 289 64.6 (1.3) 289 63.7 (1.3)
Patients with DGF 48 56.1 (20.0) 38 60.5 (22.9)
Patients without DGF 241 66.3 (21.5) 251 64.2 (21.9)
Creatinine Clearance (MDRD-4), mean (SD), mL/min
Patients completing the study 250 55.3 (1.2) 266 54.0 (1.2)
Patients with month 6 data
a 289 53.9 (1.1) 289 53.0 (1.2)
Serum Creatinine, mean, (SD), μmol/L
Patients completing the study 250 133.9 (51.4) 266 137.2 (52.7)
Patients with month 6 data
a 289 138.2 (57.7) 289 144.7 (93.7)
Patients with DGF 48 169.9 (77.0) 38 151.5 (54.8)
Patients without DGF 241 131.9 (51.0) 251 143.7 (98.3)
FAS
DGF: Delayed graft function. MDRD: Modiﬁcation of Diet in Renal Disease.
aCompleters and withdrawn patients with available data at 6 months after transplantation.
Table 3: Selected secondary endpoints.
Tacrolimus/Sirolimus N = 318 Tacrolimus/MMF N = 316
Acute Rejection, Number (%) 82 (25.8) 77 (24.4)
Biopsy conﬁrmed acute rejection, Number (%): 48 (15.1)
a 39 (12.3)
a
Spontaneously resolving 1 (0.3) 0 (0.0)
Corticosteroid sensitive 34 (10.7) 32 (10.1)
Corticosteroid resistant 14 (4.4) 8 (2.5)
Resolved with further treatment 12 (3.8) 8 (2.5)
Other 1 (0.3) 0 (0.0)
H i s t o l o g i c a lg r a d e ,N u m b e r( % ) :
Mild (Banﬀ I) 30 (9.4) 20 (6.3)
Moderate (Banﬀ II) 17 (5.3) 17 (5.4)
Severe (Banﬀ III) 1 (0.3) 2 (0.6)
Patient survival
b, % 99.0 99.0
Graft survival
b, % 92.7 93.3
FAS
aMore than one BCAR episode was reported for some patients.
bKaplan-Meier estimates.
Tac/SRL group and 3 patients in the Tac/MMF group. The
cause of death of the patient in the Tac/SRL group was
hyperkalemia and the cause of death for all 3 patients in
the Tac/MMF group was cardiorespiratory; no deaths were
assessed by the investigator to have been related to the study
medication. Two patients died in the Tac/SRL group after
their withdrawal from the study: the cause of death in both
cases was a surgical complication.
Kaplan-Meier estimates of graft survival rates at month 6
were 92.7% (Tac/SRL [95% CI: 89.8% to 95.6%]) and 93.3%
(Tac/MMF [95% CI: 90.5% to 96.1%]). Graft loss due to
long-term dialysis or transplantectomy occurring during
the study was comparable at 17/318 patients (5.3%) in the
Tac/SRL group and 16/316 patients (5.1%) in the Tac/MMF
group.
3.6. Safety. There was no diﬀerence in the overall incidence
of adverse events which was approximately 93% in
each treatment group. A signiﬁcant diﬀerence in the
occurrence of several adverse events was found (Table 4).
Hypercholesterolemia and peripheral edema occurred
signiﬁcantly more often in patients in the Tac/SRL group
(P<. 05, Fisher’s exact test). Conversely, hyperkalemia,
CMV infection, nasopharyngitis, leukopenia, and diarrhea
occurred signiﬁcantly more often in patients in the
Tac/MMF group (P<. 05 and P<. 001 for CMV infection
and leukopenia, Fisher’s exact test for all comparisons).
Twice as many patients receiving Tac/SRL withdrew
due to an adverse event (48/318 [15.1%]) than patients
who received Tac/MMF (20/316 [6.3%]). By body system
(MedDRA coded), the most commonly reported adverse6 Journal of Transplantation
Full analysis set (FAS)
(n = 318/100%)
Full analysis set (FAS)
(n = 316/100%)
Patients randomized
Tacrolimus/MMF Tacrolimus/SRL
13 (4.1%)
1 (0.3%)
5 (1.6%)
4 (1.3%)
3 (0.9%)
1 (0.3%)
Not transplanted/no study
medication: 15 pts
Not transplanted/no study
medication: 10 pts
Discontinuations, (%)
Adverse events
Graft loss
Protocol violation
Lost to follow up
Death
Other
46 (14.6%)
20 (6.3%)
14 (4.4%)
4 (1.3%)
3 (0.9%)
3 (0.9%)
2 (0.6%)
67 (21.1%)
48 (15.1%)
8 (2.5%)
3 (0.9%)
2 (0.6%)
1 (0.3%)
1 (0.3%)
4 (1.3%)
Discontinuations, (%)
Adverse events
Graft loss
Protocol violation
Informed consent withdrawn
Lost to follow up
Death
Other
MMF/antibody induction
History of malignancy
Antibody induction
History of malignancy
Non-compliance
No tacrolimus records
n n
(n = 659)
(n = 326) (n = 333)
Completed: (n = 251/78.9%) Completed: (n = 270/85.4%)
P e rp r o t o c o ls e t
(n = 304/95.6%)
P e rp r o t o c o ls e t
(n = 303/95.9%)
Figure 1: The full analysis set, which consisted of all patients who received at least one dose of study drug, included 318 patients in the
Tac/SRL group and 316 patients in the Tac/MMF group. More patients in the Tac/SRL group withdrew from the study prematurely, the
majority because of an adverse event.
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Figure 2: Data presented are for the FAS population. Mean
tacrolimus trough levels in the Tac/SRL group were higher than the
recommended upper level throughout the study. In the Tac/MMF
group, mean trough levels were within the recommended ranges
from month 3 onward.
event leading to study withdrawal in both groups was a
renal or urinary disorder (by preferred term these were renal
artery/renal vein thrombosis, renal artery stenosis, renal
infarct, and renal tubular necrosis).
Similar percentages of patients in the Tac/SRL and
Tac/MMF groups experienced serious adverse events, 45.9%
(146/318) and 43.4% (137/316), and similar percentages of
patients experienced adverse events that were assessed by the
investigator to be causally related to the study medication,
69.2% (220/318) and 67.7% (214/316), respectively. Two
patients in each group were diagnosed with a malignancy
during the study. In the Tac/SRL group, 1 patient was
diagnosed with lymphoproliferative disease and 1 with an
abdominal tumor. In the Tac/MMF group 2 patients were
diagnosed with a renal carcinoma.
Changes in mean serum lipid values were negligible
between baseline and month 6 in both treatment groups
(Table 5). There were no diﬀerences found between the
groups in the incidence of hypertension and approximately
three-quarters of patients in both groups were receiving
treatment for hypertension at study completion. The inci-
dence of de novo diabetes mellitus was lower in the Tac/SRL
than in the Tac/MMF group.
No signiﬁcant diﬀerences between groups were observed
in any mean hematology value (Table 5). As classiﬁed by theJournal of Transplantation 7
Table 4: Commonly reported
a adverse events—number (%) of patients.
Tacrolimus/Sirolimus N = 318 Tacrolimus/MMF N = 316
Adverse event
Metabolism or nutrition 167 (52.5) 156 (49.4)
Hyperglycemia 38 (11.9) 46 (14.6)
Diabetes mellitus 25 (7.9) 32 (10.1)
Hyperkalemiab 15 (4.7) 28 (8.9)
Hypercholesterolemiab 35 (11.0) 18 (5.7)
Infections 149 (46.9) 162 (51.3)
Urinary tract 83 (26.1) 83 (26.3)
Cytomegalovirusc 9 (2.8) 38 (12.0)
Nasopharyngitisb 7 (2.2) 19 (6.0)
Blood and lymphatic systemb 76 (23.9) 102 (32.6)
Anemia 52 (16.4) 68 (21.5)
Leukopeniac 5 (1.6) 27 (8.5)
Gastrointestinal disorders 83 (26.1) 90 (28.5)
Diarrheab 38 (11.9) 57 (18.0)
Vascular disorders 74 (23.3) 54 (17.1)
General or site of drug administration 65 (20.4) 50 (15.8)
Peripheral edemab 22 (6.9) 10 (3.2)
Nervous system 44 (13.8) 45 (14.2)
Musculoskeletal 42 (13.2) 31 (9.8)
Serious Adverse Event
Infection 48 (15.1) 37 (11.7)
Cytomegalovirus infectionc 3 (0.9) 16 (5.1)
Vascular disorders 23 (7.2) 14 (4.4)
Gastrointestinal disorders 17 (5.3) 16 (5.1)
Cardiac disordersb 2 (0.6) 10 (3.2)
FAS
aListed are the most common adverse events occurring in ≥10% of patients or with a signiﬁcant diﬀerence between groups. Serious adverse events are listed
if they occurred in ≥5% of patients. Reports of renal dysfunction/impairment, surgical complications, and abnormal laboratory values are not presented here
as an adverse event.
bP <. 05. cP <. 001 (Fisher’s exact test for all comparisons).
Table 5: Clinical laboratory results, concomitant medications, and safety results.
n Tacrolimus/Sirolimus N = 318 n Tacrolimus/MMF N = 316
Total cholesterol, mean (SD), mmol/L 285 5.2 (1.4) 291 5.0 (1.1)
Change from baseline 241 0.5 (1.5) 240 0.3 (1. 5)
LDL, mean (SD), mmol/L 248 3.0 (1.0) 255 2.9 (1.0)
Change from baseline 178 0.3 (1.1) 183 0.2 (1.1)
HDL, mean (SD), mmol/L 258 1.4 (0.5) 265 1.3 (0.4)
Change from baseline 192 0.1 (0.5) 195 0.0 (0.4)
Triglycerides, mean (SD), mmol/L 285 2.3 (1.6) 291 2.1 (1.5)
Change from baseline 245 0.2 (1.5) 244 −0.1 (1.7)
Hematology, mean (SD):
WBC, ×109/L 314 7.3 (3.1) 313 6.7 (2. 7)
Platelets, ×109/L 314 238.7 (81.8) 313 231.9 (74.9)
De novo diabetes mellitusa, Number (%) 287 51 (17.8) 278 69 (24.8)
De novo diabetes mellitusb, Number (%) 287 5 (1.7) 278 20 (7.2)
FAS
aPatientswithoutpre-existingdiabetesmellitustreatedwithantidiabeticmedicationsfor>30consecutivedaysatanytimeduringthestudy. bPatientswithout
pre-existing diabetes mellitus treated with antidiabetic medications for >30 consecutive days and still receiving this treatment at end of study.8 Journal of Transplantation
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Figure 3: Estimated rate of patients free from biopsy-conﬁrmed
acute rejection (Kaplan-Meier method). The estimated rate of
patients free from BCAR (Kaplan-Meier method) at 6 months was
83.8% in the Tac/SRL group and 87.1% in the Tac/MMF group
(diﬀerencebetweengroups−3.0%;95%conﬁdenceinterval: −8.9%
to 2.4% [Greenwood formula]).
investigator,theincidenceofviralinfectionswassigniﬁcantly
higher in the Tac/MMF group: 10.4% compared with 19.6%
(P = .001, Fisher’s exact test).
The duration of initial hospitalization as well as the
number of episodes of subsequent hospitalizations was
similar between the two groups.
4. Discussion
This large multicenter study investigated the non-inferiority
of tacrolimus combined with ﬁxed-dose sirolimus against
a standard regimen of tacrolimus combined with MMF
by measuring creatinine clearance at 6 months in renal
transplant patients. Results showed that a tacrolimus and
sirolimus regimen is noninferior to the widely used combi-
nation of tacrolimus and MMF.
There was no apparent diﬀerence in renal function when
comparing groups receiving the two diﬀerent tacrolimus-
based combinations. The phase II comparative trial which
provided the basis for our trial showed no indication of
an inﬂuence of sirolimus on renal function when combined
withtacrolimususingﬁxeddosesofsirolimus(0.5mg1.0mg
or 2mg) for 6 months [8], and serum creatinine levels
in the sirolimus group in our study were 14% lower than
those reported using tacrolimus combined with sirolimus
1mg[5]. The similar results in renal function we observed
contrast with results from a phase III clinical trial in which
both serum creatinine and creatinine clearance were better
with MMF than with sirolimus at 6 months [6] ,at r e n d
which continued and was reported in the one-year results
of that study [13]. Analysis of retrospectively collected
Scientiﬁc Renal Transplant Registry (SRTR) data showed
worse graft survival at 1 year with a tacrolimus/sirolimus
combination (91.8%) versus a tacrolimus/MMF combina-
tion (94.2%) with diﬀerences in graft survival at 3 years
reaching statistical signiﬁcance (80.3%, tacrolimus/sirolimus
versus 85.9%, tacrolimus/MMF) [7]. Decreasing the doses
of the adjuvant agents early in the posttransplant phase
and lowering tacrolimus exposure may have inﬂuenced
our results. We did ﬁnd numerically higher rates and a
longer duration of DGF with Tac/SRL than with Tac/MMF.
Admittedly, caution should be applied before drawing any
conclusion on the beneﬁt on renal function of one regimen
over the other as used in this study. We acknowledge that the
6-month study duration makes it diﬃcult to project renal
function or graft survival longer-term and the study design
m a k e si td i ﬃcult to identify variables which might abate or
accelerate nephrotoxicity.
For the primary analysis, we used data from study
completers. While an analysis using imputation to account
for missing data might yield additional information, it
is unlikely that this procedure would provide a diﬀerent
study conclusion. As shown in Table 2, the diﬀerence in
creatinine clearance between “completers” and “patients
withmonth 6 data” is minimal. We suspectthat the inclusion
of imputed data would not change the observed diﬀerence in
creatinine clearance between the treatment groups; the con-
ﬁdence interval, however, would be aﬀected becoming wider
due to increased standard deviations or narrower due to
increased sample size with the inclusion of imputed missing
values.
Using the experience gained from a phase II trial [8],
we implemented a novel approach to dosing sirolimus using
two stages to reduce the ﬁxed-dose (i.e., 2mg sirolimus for
the ﬁrst 28 days and 1mg/day thereafter). Protocol-deﬁned
troughlevelsfortacrolimuswerelowerintheTac/SRLgroup,
an approach supported by clinical research ﬁndings [5, 14].
Dosing of MMF and tacrolimus in the Tac/MMF group was
based on the favorable results of previous studies [15, 16].
The intent of both treatment schemas was to achieve a
balance between protection from acute allograft rejection
and acceptable tolerability.
Several aspects of regimen tolerability observed in this
study are worth mentioning. Firstly, no patient in either
treatment group switched the adjuvant immunosuppressant
and only four patients in the MMF group discontinued this
drug. These results contrast results of a previous study in
which a signiﬁcantly higher rate of drug discontinuation
was observed with tacrolimus and sirolimus compared to
tacrolimus and MMF (21.1% versus 10.8%) [6]. Secondly,
adherence to protocol-deﬁned steroid withdrawal was disap-
pointingwithonly50%ofpatientsineachgroupsteroid-free
by month 4. This ﬁnding together with the short follow
up after steroid discontinuation makes it inappropriate to
comment on the safety of withdrawing steroids at 3 months.
The third aspect of regimen tolerability which should
be mentioned is the higher tacrolimus exposure throughout
the study in the Tac/SRL group. Although tacrolimus levels
in this study were 19% lower than what was reported in
t h ep h a s eI Is t u d y[ 8], the levels may nonetheless reﬂect
hesitancy among clinicians to reduce tacrolimus dose in the
absence of steroids despite potential nephrotoxicity when
administering a CNI and mTOR combination. Tacrolimus
levels were also reported to be at the upper end of the targetJournal of Transplantation 9
range with low dose tacrolimus in the large, randomized
multicenter ELITE-Symphony study [17].
The incidences of BCAR we report are in line with
prospective study data with incidences ranging from 12% to
24% [15, 17–19] and retrospective review data reporting an
incidence of 17% using immunosuppressive regimens with-
out antibody induction [20]. Further, rates of BCAR in the
Tac/SRL group are comparable to those reported in studies
in which sirolimus doses remained constant for 6 months
(15.7%) [5]. Although incidences of clinical rejection in
our study were similar, not all episodes of clinical rejection
were veriﬁed by biopsy as was speciﬁed in the protocol. Our
results indicate that it may be feasible to use a ﬁxed sirolimus
dose reduction schema without compromising eﬃcacy; this,
however, remains to be proven in prospective trials.
Theincidenceandtypeofadverseeventsreportedduring
the study reﬂect the known safety proﬁle of both adjunctive
therapies (sirolimus and MMF).Study results do not provide
clear conclusions in terms of a beneﬁt on safety outcomes
of one regimen over the other. Known side eﬀects of MMF
therapy, leucopenia, and subsequent infections including
CMV infection [13, 21]w e r em o r ef r e q u e n t l yr e p o r t e d
with Tac/MMF. Lastly, we observed greater premature study
withdrawal in the Tac/SRL than in the Tac/MMF group, as
was also reported in another European randomized study
[5].Thewithdrawalratesinthatstudy(10.5%withsirolimus
versus 4.9% with MMF) were somewhat lower than the rates
we report.
In conclusion, results of this study show similarly good
renal function at 6 months in renal transplant recipients
when tacrolimus is combined with either sirolimus or with
MMF. The use of a novel ﬁxed-dose dosing schema for
sirolimus was not associated with increased risk of rejection.
Both tacrolimus-based regimens provided comparable bene-
ﬁt in this study population.
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